47
views
0
recommends
+1 Recommend
3 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Sexuelle Funktionsstörungen bei Substitution mit Methadon und Levomethadon

      research-article

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Zusammenfassung. Hintergrund: Sexuelle Funktionsstörungen sind bei der Substitutionsbehandlung der chronischen Opioidabhängigkeit häufig. Neben Methadon ist Levomethadon derzeit die in Deutschland am häufigsten eingesetzte Substanz zur Substitution. Bisher gibt es unserer Kenntnis nach keine Studie, die sexuelle Funktionsstörungen bei Methadon im Vergleich zu Levomethadon untersucht hat. Zielsetzung: Erfragung von sexuellen Funktionsstörungen. Material und Methoden: Wir führten eine Befragung von männlichen opioidabhängigen Patienten unter Substitutionsbehandlung mit Methadon oder Levomethadon in Berlin durch. Sexuelle Funktionsstörungen wurden mit dem International Index of Erectile Function (IIEF) sowie in der Selbsteinschätzung erhoben. Ergebnisse: Es nahmen 66 Patienten an der Erhebung teil. 30 (45.5 %) erhielten Methadon, 36 (54.5 %) Levomethadon. Erektile Dysfunktion trat signifikant häufiger unter Methadon auf ( p = .029). Bezüglich der Selbsteinschätzung sexueller Funktionsstörungen wiesen die Patienten, die über solche berichteten ( N = 40, 71.4 %), eine signifikant höhere Dosierung der substituierten Substanz auf ( p = .014; Dosierung 125 mg ± 45.3 mg vs. 93.3 mg ± 24.7 mg). Schlussfolgerung: Unsere Studie weist auf eine Überlegenheit von Levomethadon bzgl. der durch die Patienten selbst berichteten erektilen Funktion hin. Bei Auftreten von sexuellen Funktionsstörungen könnten ein Substanzwechsel oder eine Dosisreduktion hilfreich sein.

          Sexual dysfunction related to opioid maintenance treatment with methadone and levomethadone

          Abstract. Background: Sexual dysfunction is a common side effect in opioid maintenance treatment (OMT). Apart from methadone, in Germany levomethadone is the most often prescribed substance for OMT. Despite the high clinical relevance of these side effects, to our knowledge no study has investigated the influence of methadone compared to that of levomethadone on sexual function. Objectives: To collect data on sexual dysfunction with a standardized questionnaire and self-evaluation. Material and Methods: We conducted a study with chronically affected opioid dependent male patients currently receiving OMT with methadone and levomethadone in Berlin. We used the International Index of Erectile Function (IIEF) as well as self-ratings. Results: 66 patients took part, 30 (45.5 %) in the methadone, 36 (54.5 %) in the levomethadone group. Erectile dysfunction occurred significantly more often in the methadone group ( p = .029). Patients reporting sexual desire ( N = 40, 71.4 %) in self-ratings received a significantly higher dosing of OMT ( p = .014, 125 mg ± 45.3 mg vs. 93.3 mg ± 24.7 mg). Conclusions: Our study hints to a superiority of levomethadone over methadone concerning self-reported erectile function. If sexual dysfunction is present in a subject being treated with OMT, a switch to levomethadone or an overall reduction of the dosage could be helpful.

          Related collections

          Most cited references27

          • Record: found
          • Abstract: found
          • Article: not found

          Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study.

          Opioid maintenance treatment (OMT) is generally considered to reduce mortality in opiate dependents. However, the level of mortality reduction is still uncertain. This study investigates mortality reductions in an "intention-to-treat" perspective including all dropouts. The mortality reducing effects of OMT are examined both within treatment and post-treatment. The study separates overdose and total mortality reductions. The study is a prospective cross-registry study with up to 7 years follow-up. All opiate dependents in Norway who applied for OMT (a total of 3789 subjects) were cross-linked with data from the death registry from Statistics Norway. Date and cause of death were crossed with dates for initiation and termination of OMT, and subjects' age and gender. A baseline was established from the waiting list mortality rate. Intention-to-treat was investigated by analysing mortality among the entire population that started OMT. Mortality in treatment was reduced to RR 0.5 (relative risk) compared with pre-treatment. In the "intention-to-treat" perspective, the mortality risk was reduced to RR 0.6 compared with pre-treatment. The patients who left the treatment programme showed a high-mortality rate, particularly males. OMT significantly reduces risk of mortality also when examined in an intention-to-treat perspective. Studies that evaluate effects of OMT only in patients retained in treatment tend to overestimate benefits. Levels of overdose mortality will influence the risk reduction. Cross-registry studies as the current one are an important supplement to other observational designs in this field.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Reducing the risk of AIDS through methadone maintenance treatment.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment.

              Use of opiates/opioids is associated with hypoactive sexual desire, erectile and orgasmic dysfunction. To determine prevalence and investigate etiology of sexual dysfunction in men on methadone or buprenorphine maintenance treatment (MMT, BMT). International Index of Erectile Function (IIEF), hormone assays, Beck Depression Inventory. A total of 103 men (mean age 37.6 +/- 7.9) on MMT (N = 84) or BMT (N = 19) were evaluated using the IIEF, hormone assays, Beck Depression Inventory, body mass index (BMI), demographic, and other substance use measures. Mean total IIEF scores for partnered men were lower for MMT (50.4 +/- 18.2; N = 53) than reference groups (61.4 +/- 16.8; N = 415; P < 0.0001) or BMT (61.4 +/- 7.0; N = 14; P = 0.048). Among partnered men on MMT, 53% had erectile dysfunction (ED) compared with 24% of reference groups; 26% had moderate to severe ED, 12.1% in under 40s and 40.0% among those 40+ years. On multiple regression, depression, older age, and lower total testosterone were associated with lower IIEF and EF domain; on multivariate analysis, there were no significant associations between IIEF or EF and free testosterone, opioid dose, cannabis or other substance use, viral hepatitis, or BMI. Total testosterone accounted for 16% of IIEF and 15% of EF variance. Men without sexual partners had lower Desire and Erection Confidence scores and less recent sexual activity, suggesting potentially higher prevalence of sexual dysfunction in this group. Men on MMT, but not BMT, have high prevalence of ED, related to hypogonadism and depression. Practitioners should screen for sexual dysfunction in men receiving opioid replacement treatment. Future studies of sexual dysfunction in opioid-treated men should examine the potential benefits of dose reduction, androgen replacement, treatment of depression, and choice of opioid.
                Bookmark

                Author and article information

                Contributors
                Journal
                suc
                SUCHT
                Zeitschrift für Wissenschaft und Praxis
                Hogrefe AG, Bern
                0939-5911
                1664-2856
                2016
                : 62
                : 5
                : 295-303
                Affiliations
                [ 1 ]geteilte Autorenschaft Klinik für Psychiatrie und Psychotherapie, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin
                Author notes
                Nikola Schoofs, Charité Universitätsmedizin Berlin,, St. Hedwig-Krankenhaus,, Klinik für Psychiatrie und Psychotherapie,, Große Hamburger Straße 5 – 11, 10115 Berlin, Deutschland, E-Mail nikola.schoofs@ 123456charite.de
                Article
                suc_62_5_295
                10.1024/0939-5911/a000447
                20fdf684-55ce-48d8-9d2b-5f61d29d2e3e
                Copyright @ 2016
                History
                Categories
                Originalarbeit

                Medicine,Psychology,Clinical Psychology & Psychiatry
                Opioidabhängigkeit,sexual dysfunction,Substitution,OMT,sexuelle Funktionsstörungen,opioid dependence,IIEF

                Comments

                Comment on this article